01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Tiziana Life Sciences – Final Results June 18, 2020 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

Thursday 18th June, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Final Results for the Year Ended 31 December 2019  London / New York 18 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces its financial results for the year ended 31 December 2019. This announcement contains inside…

Continue reading

Tiziana Life Sciences Plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Correction – Exercise of Warrants and Issue of Equity and Total Voting Rights The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is 1,234,399, yielding £578,700 cash proceeds. All other details in the announcement remain unchanged. The amended announcement is set out below:…

Continue reading

Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Tiziana Announces Publication of Registration Statement on Form F-1 and Proposed U.S. Public Offering of ADSs New York and London, August 6, 2019 – Tiziana Life Sciences…

Continue reading

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Milciclib was well tolerated and no drug related deaths were reported 28 out 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment New York/London, 22 July 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced…

Continue reading